Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR3 | P25089 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1635113 | 0.74 | NPSR1 (0.35) | TSHRALDH1A1TDP1 | |
| SCHEMBL1635617 | 0.74 | ALDH1A1 (0.33) | FPR3FPR2TSHRALDH1A1 | |
| SCHEMBL1634348 | 0.71 | LMNA (0.37) | FPR3FPR2TSHRALDH1A1 | |
| SCHEMBL1634488 | 0.70 | CYP2C9 (0.37) | FPR3FPR2TSHRALDH1A1 | |
| SCHEMBL1633726 | 0.70 | CYP2C9 (0.37) | FPR3FPR2TSHRALDH1A1 | |
| SCHEMBL1636664 | 0.70 | CYP2C9 (0.37) | FPR3FPR2TSHRALDH1A1 | |
| SCHEMBL1634966 | 0.70 | CYP2C9 (0.37) | FPR3FPR2TSHRALDH1A1 | |
| SCHEMBL1634696 | 0.70 | CYP2C9 (0.37) | FPR3FPR2TSHRALDH1A1 | |
| SCHEMBL1634432 | 0.68 | FPR3 (0.31) | FPR3FPR2 | |
| SCHEMBL1634827 | 0.68 | GAA (0.32) | FPR3FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040209858-A1 | Cycloalkylamides and their therapeutic applications | ABBOTT LABORATORIES | 2004-10-21 | — | — | US | claimed |
| US-20040077618-A1 | Cycloalkylamides and their therapeutic applications | ABBOTT LABORATORIES | 2004-04-22 | — | — | US | claimed |
| US-20040209858-A1 | Cycloalkylamides and their therapeutic applications | ABBOTT LABORATORIES | 2004-10-21 | — | — | US | disclosed |
| US-20040077618-A1 | Cycloalkylamides and their therapeutic applications | ABBOTT LABORATORIES | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209858-A1 | Cycloalkylamides and their therapeutic applications | GAP43, SCN1B, GRIN2B | FPR3 503/4885FPR2 601/4885TSHR 3907/4885 |
| US-20040077618-A1 | Cycloalkylamides and their therapeutic applications | GAP43, SCN1B, GRIN2B | FPR3 503/4885FPR2 601/4885TSHR 3907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.